BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8182895)

  • 1. [Antibacterial activity of tosufloxacin against fresh clinical isolates].
    Yamashiro Y; Shimakura M; Minami S; Fukuoka Y; Yasuda T; Watanabe Y; Narita H; Akama M
    Jpn J Antibiot; 1994 Mar; 47(3):245-54. PubMed ID: 8182895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M; Hara T; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antimicrobial activities of tosufloxacin against recently obtained clinical isolates].
    Ishihara R; Suzuki Y; Tanaka S; Fukayama S; Deguchi K; Oda S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1996 Jul; 49(7):715-42. PubMed ID: 8828073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC; Chin NX
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of T-3761, a new fluoroquinolone.
    Muratani T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
    Masuda N; Takahashi Y; Otsuki M; Ibuki E; Miyoshi H; Nishino T
    Antimicrob Agents Chemother; 1996 May; 40(5):1201-7. PubMed ID: 8723467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
    Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.